Zura Bio Limited (ZURA)
NasdaqCM · USD · Healthcare · Biotechnology
$3.56 (+5.95%) as of
Key statistics
- Market cap
- 341.15M
- Forward P/E
- -5.16
- EPS (TTM)
- -1.1200
- Dividend yield
- 0.00%
- 52-week range
- 3.2500 – 7.4400
- Beta
- 0.01
- Profit margin
- 0.00%
- Analyst target
- $19.00
- Volume
- 4.27M
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Henderson, NV, United States
- Employees
- 40
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.